Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Biohm is an eco-conscious bio-technology company that is revolutionising construction through nature-inspired innovation. The company has adopted methods such as circular construction system, biomimicry, and triagomy. Some of the company’s carbon-negative bio-based materials include building insulation made out of Mycelium (the root structure of mushrooms) and ORB (Organic Refuse Biocompound), a 100% natural sheet material made out of food and agricultural surplus. For its innovation, Biohm won the Waitrose and Partners Plan Plastic Prize: The Million Pound Challenge and a Power to Change grant worth £600,000 to build sustainable living premises. It has also been shortlisted as one of The United Nation’s ‘Young Champions of the Earth’. The company will use 38% of the investment to grow its team, 22% to scale Research and Development (R&D), 22% to protect its Intellectual Property (IP), and 18% for product accreditation.
days to go:
Expired
investment:
£790,700
TV.FIT is a streaming service and app that allows its users to access 100 hours of health & wellbeing content from global fitness experts & celebrities. Its subscription service is accessible in 66 countries across 6 continents. The platform aims to cater to all aspects of fitness, from mental health support for those who have yet to start to improve their fitness to creating content for those who are already working on their fitness regime. Its programs are created by some of the world’s most well-known fitness figures including George St-Pierre, Caroline Pearce, Gemma Atkinson, and Pierre Pozzuto. The platform has a global multimedia reach of over 8 million followers via partners such as TruFusion and CoolEvents, with another 6 million+ prospective users in the pipeline. TV.FIT also disseminates NHS-recommended mental-health-focused content on its platform. With the funds received, the platform aims to invest 31% of it in marketing, 28% in international content development, 22% in capital reserves, 18% in content production, and 1% towards repayment of debt.
days to go:
Expired
investment:
£2,208,212
MysteryVibe creates doctor-recommended sexual health devices. The company combines research and engineering by onboarding leading doctors to design devices that address major sexual health issues such as erectile dysfunction, dryness and pain during intercourse. MysteryVibe has changed over 50,000 lives in 65 countries, witnessed $1 million worth of direct sales in 2020, and became the first sexual health startup to be featured on a BBC documentary. The company has received 20+ international awards including, the coveted Design Week Awards where its product, 'Crescendo', beat the Apple Watch. MysteryVibe has featured in media entities like Men's Health, Women's Health, The Daily Dot, and Forbes, to name a few. The company will use 25% of the investment to expand and scale its digital marketing campaign, 25% to launch two new products, 25% to expand its team, and 25% on building its inventory.
days to go:
Expired
investment:
£498,020
HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.
days to go:
Expired
investment:
£144,265
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.
days to go:
Expired
investment:
£290,278
Future You Cambridge is a company that sells clinically proven health supplements directly to consumers. Since its launch in 2016, it has sold products to over 100,000 customers. The company's Lactolycopene product received a patent in December 2017 and its Fertility+ product was also covered by the European Journal of Nutrition in a clinical paper and was shown to have resulted in a 40% increase in male fertility. The company's offerings now stand at 24 products, including the popular CBD product and its first product for pets, Curcupet-K9. Additionally, the company won the 2018 Cambridge Service Excellence and Independent High Growth Business of the Year Awards and has 5-star ratings on Trustpilot. They will use the investment to scale up direct advertising campaigns, expand its product range by more than 10 new products, and invest in their website to make it more intuitive.
days to go:
Expired
investment:
£655,011
Nova is a world-leading and award-winning tidal energy company. It designs, builds, and operates tidal turbines that generate electricity from the flow of the tide and the natural ebb. Nova's underwater turbines work in harmony with marine environment and have zero visual impact. In 2018, Nova received international recognition at the G7 summit and won ‘Outstanding Project’ at the Green Energy Awards the same year. Nova aims to become cost-competitive with traditional baseload fossil fuels. With the proceeds, the company will fulfil its purpose of Business Growth (25%), Project Delivery (50%), and Commercial Readiness (25%).
days to go:
Expired
investment:
£1,255,666
